rct
2013
Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study
Garg S, Syngle A, Vohra K
Published in Clinical Journal of Pain
Key Findings
24 weeks of benfotiamine plus pyridoxamine plus methylcobalamin reduced serum AGEs and improved WOMAC pain and function scores versus placebo in primary osteoarthritis.
Conclusions
An AGE-inhibitor combination lowered circulating AGEs with parallel symptom improvement.
Limitations
Small single-centre trial (n=30), combination product, surrogate biomarker focus.
Outcomes Measured
The objective of this study was to evaluate the efficacy and tolerability of AGEs inhibitor (benfotiamine [50 mg]+pyridoxamine [50 mg]+methylcobalamin [500 microg]) in OA patients.
Related Health Concerns
Study Details
Year:2013
Sample Size:30
Duration:24 weeks
Quality Score:5/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.